Article

Visible blue light inactivates SARS-CoV-2 variants and inhibits Delta replication in differentiated human airway epithelia

2022-01-31

Abstract excerpt

The emergence of SARS-CoV-2 variants that evade host immune responses has prolonged the COVID-19 pandemic. Thus, the development of an efficacious, variant-agnostic therapeutic for the treatment of early SARS-CoV-2 infection would help reduce global health and economic burdens. Visible light therapy has the potential to fill these gaps. In this study, visible blue light centered around 425 nm efficiently inactivat...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d40fb250-a7c4-5109-a7a9-f634c225407f
DOI: 10.1101/2022.01.25.477616

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Visible blue light inactivates SARS-CoV-2 variants and inhibits Delta replication in differentiated human airway epitheliaDOI 10.1101/2022.01.25.477616Read

UV-C Light Intervention as a Barrier against Airborne Transmission of SARS-CoV-2Semantic proximity Read

Nasally-delivered interferon-λ protects mice against upper and lower respiratory tract infection of SARS-CoV-2 variants including OmicronSemantic proximity Read

Far-UVC light efficiently and safely inactivates airborne human coronavirusesSemantic proximity Read

Prospects for RNAi Therapy of COVID-19Semantic proximity Read

Efficacy of Biophotonics as a Therapeutic Adjunct in Resolving Microbial and Viral Infectious IllnessesSemantic proximity Read

FAR-UV Technology and Germicidal Ultraviolet (GUV) Energy: A Policy and Research Review for Indoor Air Quality and Disease Transmission ControlSemantic proximity Read

Methylene Blue has a potent antiviral activity against SARS-CoV-2 and H1N1 influenza virus in the absence of UV-activation in vitroSemantic proximity Read

UV-C Irradiation-Based Inactivation of SARS-CoV-2 in Contaminated Porous and Non-Porous SurfacesSemantic proximity Read

A human primary airway microphysiological system infected with SARS-CoV-2 distinguishes the treatment efficacy between nirmatrelvir and repurposed compounds fluvoxamine and amodiaquineSemantic proximity Read

Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial CulturesSemantic proximity Read

Divalent siRNAs are bioavailable in the lung and efficiently block SARS-CoV-2 infectionSemantic proximity Read

Methylene blue, Mycophenolic acid, Posaconazole, and Niclosamide inhibit SARS-CoV-2Omicron variant BA.1 infection of human airway epithelial explant culturesSemantic proximity Read